Soluble epoxide hydrolase: a new target for cardioprotection

Area of Science:

• Cardiovascular Science
• Biochemistry
• Pharmacology

Background:

• Arachidonic acid metabolism yields bioactive eicosanoids via COX, lipoxygenase, and cytochrome P450 (CYP) pathways.
• CYP pathways, specifically omega-hydroxylase and epoxygenase, play roles in cardiac function and ischemia.
• Epoxyeicosatrienoic acids (EETs) are cardioprotective, but rapidly metabolized by soluble epoxide hydrolase (sEH).

Purpose of the Study:

• To investigate the cardioprotective potential of inhibiting the metabolism of endogenous epoxyeicosatrienoic acids (EETs).
• To evaluate the efficacy of soluble epoxide hydrolase (sEH) inhibitors in animal models of cardiac ischemia and related diseases.

Main Methods:

• Utilized gene knockout mice lacking EPHX2 (the gene encoding sEH) to block endogenous EET metabolism.
• Administered specific sEH inhibitors, including 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), in various animal models.
• Assessed cardiac function and infarct size following ischemia/reperfusion injury in treated and control groups.

Main Results:

• Inhibition of CYP omega-hydroxylase and stimulation of the CYP-epoxygenase pathway conferred cardioprotection in animal models.
• Blocking endogenous EET metabolism in EPHX2-/- mice and using sEH inhibitors like AUDA resulted in cardioprotective effects.
• AUDA pretreatment dose-dependently reduced infarct size in canine hearts and enhanced the protective effects of exogenous EETs.
• AUDA and its butyl ester demonstrated infarct-reducing capabilities in rodent heart models.

Conclusions:

• Inhibition of soluble epoxide hydrolase (sEH) represents a promising therapeutic strategy for cardioprotection.
• sEH inhibitors, such as AUDA, show potential for treating a wide spectrum of cardiovascular diseases, including myocardial stunning and hypertrophy.